Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Microbot Medical ( (MBOT) ) has shared an update.
On May 14, 2026, Microbot Medical announced it would host an analysts and investors conference call and live webcast on May 18 at 3:00 p.m. ET to review recent progress in the Full Market Release of its LIBERTY Endovascular Robotic System. The session will feature the company’s executive team and two clinicians who use LIBERTY in daily practice, highlighting how the system is being deployed in real-world endovascular and interventional radiology settings.
The company also plans to address claims made in a recent unaffiliated third-party article, which it says misrepresented both company and product information and included inaccurate statements attributed to a vascular surgeon user. By bringing in current LIBERTY users and referencing external research that disputes the article’s assertions, Microbot is attempting to reassure investors, defend its technology’s reputation and ensure the market is informed with what it describes as accurate facts about its operations and flagship system.
The most recent analyst rating on (MBOT) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a commercial-stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Its flagship product, the LIBERTY Endovascular Robotic System, is a first-of-its-kind single-use, remotely operated robotic solution aimed at improving precision, efficiency and safety in endovascular care, supported by a substantial intellectual property portfolio.
Average Trading Volume: 1,816,057
Technical Sentiment Signal: Sell
Current Market Cap: $124.3M
For detailed information about MBOT stock, go to TipRanks’ Stock Analysis page.